Observational Study of Dd-cfDNA and Treg in Kidney Transplant Rejection
This study is looking at new ways to detect kidney transplant rejection early and without an invasive biopsy. Researchers are studying donor-derived cell-free DNA (dd-cfDNA) and regulatory T cells (Tregs) in people who have received a kidney transplant. Dd-cfDNA is genetic material from the donor kidney found in your blood, and Tregs are special immune cells that help prevent rejection. The goal is to see if measuring these can predict acute rejection (when your body's immune system attacks the new kidney) before it causes significant damage. This could help improve how long transplanted kidneys last. The study plans to include 150 adult kidney transplant recipients.
- Study design
- This is an observational study, meaning researchers will monitor participants without providing a specific intervention. It plans to enroll 150 adult kidney transplant recipients.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome, biopsy-proven acute rejection, will be measured at 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection
At a glance
Conditions
NCT05084768
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Loma Linda University Health
Loma Linda, Californiano site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Minh-Tri Nguyen, MD PhD · PRINCIPAL_INVESTIGATOR · Loma Linda University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Number of participants with biopsy-proven acute rejection graded with the Banff score1 year
TCMR 1A, TCMR 1B, TCMR 2A, TCMR 2B, TCMR 3B, ABMR